Glomeruli Of Diabetic Rats Of Nf-¦Êb, Icam-1 Expression And Intervention Research

Objective To investigate the effects of combined use of Valsartan and Simvastatin on NF-κB and ICAM-1 on glomeruli of diabetic rats, and study their possible mechanisms. Methods We divided the experimental rats into five groups: non-diabetic controlrats (NC); STZ-induced diabetic rats(DM); diabetic rats treated with Valsartan(V); diabetic rats treated with Simvastatin(S); diabetic rats treated with Valsartan and Simvastatin(V+S). After 4, 8 weeks, blood urea nitrogen(BUN), creatinine clear rate(Ccr), serum cholesterol, triglyceride and urinary albumin excretion(UAE) were measured. Expressions of NF-κB and ICAM-1 were detected by immunohistochemical staining. Results 4 week, BUN,Ccr,UAE and expressions of ICAM-1 in diabetic rats treated were not significantly lower than untreated diabetic rats. Expressions of NF-κB in V+S group were significantly lower than other diabetic rats. 8 weeks, BUN,Ccr,UAE,expressions of NF-κB and ICAM-1 in diabetic rats treated were significantly lower than untreated rats, especially V+S group. There were no difference in plasma lipid levels. The relationship of NF-κB and ICAM-1 was positively correlated with urinary albumin excretion and creatinine clear rate. Conclusion Valsartan and Simvastatin has renal protective effect partly through reducing NF-κB and ICAM-1 expression, independent of its lipid-lowering properties. Combination of both offer further benefits, arrest proteinuria and protect from renal function and structure impairment.